Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross‐Trial Synthesis of Benefit Probabilities and Decision Thresholds
Abstract
OBJECTIVES: To synthesize published placebo-controlled trials of vibegron monotherapy for overactive bladder (OAB) and quantify posterior probabilities of benefit and decision-threshold exceedance. METHODS: We extracted published placebo-adjusted least-squares mean differences at Week 12 from three randomized, double-blind, placebo-controlled Phase III trials evaluating vibegron monotherapy (Japan Phase III trial, Korea bridging study [50 mg], and EMPOWUR trial [75 mg]) for four voiding-diary endpoints: micturitions/day, urgency episodes/day, urgency urinary incontinence (UUI) episodes/day, and voided volume (mL). For each endpoint, a Bayesian normal-normal random-effects model estimated the pooled mean effect and between-trial heterogeneity and calculated posterior probabilities of benefit and of exceeding thresholds predefined in this analysis. RESULTS: Pooled mean effects (95% credible intervals) favored vibegron across all four voiding-diary endpoints: micturitions/day (-0.76, -1.33 to -0.28), urgency episodes/day (-0.69, -1.35 to -0.22), UUI episodes/day (-0.44, -0.93 to -0.03), and voided volume (+24.09 mL, 15.78-32.51). The posterior probabilities of benefit were 99.5%, 99.3%, 98.0%, and > 99.9%, respectively. The probabilities of exceeding thresholds were as follows: for micturitions/day, ≤ -0.5: 90.3% and ≤ -1.0: 14.2%; for urgency episodes/day, ≤ -0.5: 82.8% and ≤ -1.0: 12.7%; for UUI episodes/day, ≤ -0.3: 81.8% and ≤ -0.5: 35.4%; and for voided volume, ≥ +10 mL:…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.